product pipeline
ImmunSYS is dedicated to developing therapeutics for several types of cancer.

In addition to prostate cancer, ImmunSYS is developing the platform YourVaccx™ technology for several other types of late stage cancer.  Our pipeline includes five proprietary, highly novel product candidates currently in development.  Our platform technology has a unique mechanism of action, and we believe that it could yield important therapeutic advances and differentiation from existing therapies for many metastatic cancers.

*”IMD110” is an experimental compound code name; the drug will ultimately be named via the FDA approval process.